{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=venetoclax&page=22", "query": { "intervention": "venetoclax", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 253, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=venetoclax&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=venetoclax&page=21&page_size=10" }, "source": "local", "last_synced_at": "2026-10-20T21:28:33.733Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04801797", "title": "Venetoclax + Azacitidine vs. Induction Chemotherapy in AML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Liposomal daunorubicin and cytarabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2021-05-20", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-15T11:05:25.292Z", "location_count": 9, "location_summary": "Duarte, California • Palo Alto, California • Sacramento, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04801797" }, { "nct_id": "NCT04150887", "title": "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cusatuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoVerity, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-12-23", "completion_date": "2027-05-15", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-01T11:39:41.220Z", "location_count": 11, "location_summary": "Duarte, California • Louisville, Kentucky • Detroit, Michigan + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150887" }, { "nct_id": "NCT06384261", "title": "A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cusatuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoVerity, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2024-07-22", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-16T17:12:39.415Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06384261" }, { "nct_id": "NCT04273139", "title": "Ibrutinib + Venetoclax in Untreated WM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MYD88 Gene Mutation", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "IBRUTINIB", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2020-07-09", "completion_date": "2028-02-01", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-20T13:58:37.581Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04273139" }, { "nct_id": "NCT04872790", "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Mixed Phenotype Acute Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-02", "completion_date": "2027-12-02", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-14T19:14:36.412Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872790" }, { "nct_id": "NCT04401748", "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 531, "start_date": "2020-09-10", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-20T21:28:33.733Z", "location_count": 58, "location_summary": "Fullerton, California • Los Angeles, California • Torrance, California + 50 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401748" }, { "nct_id": "NCT05428969", "title": "A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndromes", "Relapsed/Refractory AML" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Bexmarilimab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faron Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2022-06-02", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-15T13:16:12.180Z", "location_count": 4, "location_summary": "Duarte, California • New Haven, Connecticut • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428969" }, { "nct_id": "NCT04939272", "title": "Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-06-29", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-15T04:12:47.977Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04939272" }, { "nct_id": "NCT04450173", "title": "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-02-24", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-14T12:30:53.587Z", "location_count": 4, "location_summary": "Fresno, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04450173" }, { "nct_id": "NCT03467867", "title": "A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Rituximab/Hyaluronidase Human", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2018-04-26", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-16T18:41:07.243Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467867" } ] }